Bindarit
Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8. (In Vitro) :Bindarit (10-300 μM; 48 hours) at 100 μM and 300 μM significantly inhibits platelet derived growth factor-BB (PDGF-BB) -induced rat VSMCs proliferation by 27% and 42%, respectively. (In Vivo) :Bindarit (50 mg/kg; oral administration; every day; for 4 months, 6 months, 8 months; NZB/W F1 female mice) delays the onset of proteinuria and significantly protects from renal function impairment. Bindarit completely prevents monocyte chemoattractant protein (MCP-1) up-regulation.
Product Specifications
CAS Number
130641-38-2
Product Name Alternative
AF 2838
Purity
>98% (HPLC)
Solubility
DMSO:65 mg/mL (200.38 mM) ; Ethanol:65 mg/mL (200.38 mM) ; Water:<1 mg/mL (<1 mM)
Smiles
CC (C) (OCC1=NN (CC2=CC=CC=C2) C3=C1C=CC=C3) C (O) =O
Molecular Formula
C19H20N2O3
Molecular Weight
324.37
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
2- ((1-benzyl-1H-indazol-3-yl) methoxy) -2-methylpropanoic acid
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GGT1 Recombinant Antibody, APC-Cy5.5 Conjugated
